home / stock / clrb / clrb news

CLRB News and Press, Cellectar Biosciences Inc. From 12/16/19

Stock Information
Company Name: Cellectar Biosciences Inc.
Stock Symbol: CLRB
Market: NASDAQ
Website: cellectar.com
Menu
CLRB CLRB Quote CLRB Short CLRB News CLRB Articles CLRB Message Board
Get CLRB Alerts

News, Short Squeeze, Breakout and More Instantly...
CLRB - Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study

30% overall response rate seen with an average progression free survival of 4.5 months and an acceptable and expected safety profile Additional data in patients receiving higher fractionated doses of CLR 131 anticipated in January FLORHAM PARK, N.J., Dec. 16, 2019 (GLOBE NEWSWIRE) -...
CLRB - Cellectar Presents Poster at the American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium

FLORHAM PARK, N.J., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced Jarrod Longcor, chief busines...

CLRB - Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented at the 61st Annual American Society of Hematology Conference

50% overall response rate in cohort of patients receiving fractionated 37.5 mCi/m 2 dose of CLR 131  31.3% overall response rate in multiple myeloma patients over all dose levels, including single bolus and fractionated doses of CLR 131 FLORHAM PARK, N.J., Dec. 09, 2019 (GL...

CLRB - Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference

FLORHAM PARK, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced an oral presentation at the 6...
CLRB - CRC, CGIX, XXII and PDD among midday movers

Gainers:  Cancer Genetics CGIX  +224% . More news on: Surface Oncology, Inc., Cellectar Biosciences, Inc., Magenta Therapeutics, Inc., Stocks on the move, Read more ...

CLRB - Cellectar Biosciences EPS misses by $0.04

Cellectar Biosciences (NASDAQ: CLRB ): Q3 GAAP EPS of -$0.42 misses by $0.04 . More news on: Cellectar Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

CLRB - Cellectar Reports Third Quarter 2019 Financial Results and Provides a Corporate Update

FLORHAM PARK, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the third quar...
CLRB - Cellectar Presents a New Phospholipid Drug Conjugate (PDC) at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

FLORHAM PARK, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced Jarrod Longcor, chief busines...

CLRB - Cellectar Announces Poster at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston

FLORHAM PARK, N.J., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a poster presentation at the ...

CLRB - Cellectar Presents Poster at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology

Data demonstrate phospholipid ether (PLE) molecules ability to target wide range of tumors FLORHAM PARK, N.J., Oct. 15, 2019 (GLOBE NEWSWIRE) --   Cellectar Biosciences, Inc. (NASDAQ: CLRB) , a clinical-stage biopharmaceutical company focused on the discovery, development and...
Previous 10 Next 10